Summary
14.61 -0.28(-1.88%)07/15/2025
Elanco Animal Health Incorporated (ELAN)
ELAN reported last earnings on 2025-05-07 after the market. An EPS of $0.37 was observed compared to an estimated EPS of $0.31, resulting in a surprise value of $0.06. A revenue of $1,193 million was observed compared to an estimated revenue of $1,178 million, resulting in a surprise value of $15 Million.
Elanco Animal Health Incorporated (ELAN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.72 | -1.15 | 0.00 | 77.31 | 23.29 | 9.44 | -39.13 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B- |
| Recommended Rating | Neutral |
| DCF | Strong Sell |
| ROE | Neutral |
| ROA | Neutral |
| Debt/Equity | Strong Sell |
| P/E | Neutral |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 14.51 | |
| Open | 14.64 | |
| High | 14.64 | |
| Low | 14.37 | |
| Volume | 1,840,564 | |
| Change | -0.11 | |
| Change % | -0.72 | |
| Avg Volume (20 Days) | 4,916,876 | |
| Volume/Avg Volume (20 Days) Ratio | 0.37 | |
| 52 Week Range | 8.10 - 15.78 | |
| Price vs 52 Week High | -8.08% | |
| Price vs 52 Week Low | 79.07% | |
| Range | 0.00 | |
| Gap Up/Down | 0.07 | |
Profitibility | ||
| Market Capitalization (Mln) | 7,328 | |
| Revenue per share | 8.9416 | |
| Net Income per share | 0.7534 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 19.3925 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/10 08:00 EST - prnewswire.com
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
GREENFIELD, Ind. , July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025.
07/09 08:27 EST - prnewswire.com
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated...
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
TruCan Ultra CIV is the only ½ mL bivalent Canine Influenza Virus (CIV) vaccine offering broad protection against H3N2 and H3N8. 100% virus neutralization against 33 current field isolates.1 Unlike currently available products, only TruCan Ultra CIV demonstrates zero lung lesions in vaccinated...
07/02 19:09 EST - prnewswire.com
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and...
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and...
06/26 14:38 EST - benzinga.com
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated ELAN appears to be turning a corner.
06/26 13:00 EST - prnewswire.com
Elanco Releases 2024 Impact Report and Introduces New Framework
GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them.
Elanco Releases 2024 Impact Report and Introduces New Framework
GREENFIELD, Ind. , June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE: ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them.
06/12 16:17 EST - prnewswire.com
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines...
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines...
06/10 13:01 EST - zacks.com
What Makes Elanco Animal Health (ELAN) a New Buy Stock
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Elanco Animal Health (ELAN) a New Buy Stock
Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
06/10 12:46 EST - zacks.com
ELAN vs. USPH: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
ELAN vs. USPH: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?
06/09 09:51 EST - zacks.com
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.
06/05 07:45 EST - prnewswire.com
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in...
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in...
05/28 07:25 EST - prnewswire.com
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
GREENFIELD, Ind. , May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.
Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer
GREENFIELD, Ind. , May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.
05/16 08:00 EST - prnewswire.com
Elanco to Participate in the Upcoming Investor Conferences
GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
Elanco to Participate in the Upcoming Investor Conferences
GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
05/12 04:26 EST - seekingalpha.com
Elanco: Deleveraging Takes Time
Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring...
Elanco: Deleveraging Takes Time
Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring...
05/07 13:43 EST - https://thefly.com
Elanco price target raised to $11 from $9.50 at Leerink
Leerink analyst Daniel Clark raised the firm's price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company's quarter was solid, and its exposure to tariffs was less than many feared. These two factors vs. bearish positioning are likely driving...
Elanco price target raised to $11 from $9.50 at Leerink
Leerink analyst Daniel Clark raised the firm's price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company's quarter was solid, and its exposure to tariffs was less than many feared. These two factors vs. bearish positioning are likely driving...
05/07 12:52 EST - seekingalpha.com
Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan...
Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript
Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan...
05/07 11:03 EST - benzinga.com
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco Animal Health Incorporated ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide
Elanco Animal Health Incorporated ELAN reported first-quarter 2025 adjusted earnings per share of 37 cents. That's up 9% year over year.
05/07 10:35 EST - zacks.com
Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Elanco Animal Health (ELAN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/07 08:35 EST - zacks.com
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago.
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago.
05/07 06:27 EST - prnewswire.com
Elanco Animal Health Reports First Quarter 2025 Results
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 million, Adjusted Net Income of $184 million Adjusted EBITDA of $276 million, or 23.1% of Revenue...
Elanco Animal Health Reports First Quarter 2025 Results
Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results: Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growth Reported Net Income of $67 million, Adjusted Net Income of $184 million Adjusted EBITDA of $276 million, or 23.1% of Revenue...